Alpha-1-antitrypsin augmentation treatment: does one size fit all?


distributed in large measure beyond the alveoli to bronchial and vascular structures. The increased levels of desmosine in the non-emphysematous phenotype indicate that this marker may be useful for detecting tissue degradation in the non-emphysematous COPD phenotype. The improved technical ability to measure desmosine in sputum and plasma, as well as in urine, significantly increases its usefulness as a marker of lung matrix degradation and should be more widely applied in COPD.

Cite this paper

@article{Stolk2006Alpha1antitrypsinAT, title={Alpha-1-antitrypsin augmentation treatment: does one size fit all?}, author={Jan Stolk}, journal={Thorax}, year={2006}, volume={61 12}, pages={1034} }